This perspective reveals the therapeutic intervention potential of small molecules targeting membrane proteins, highlighting structural biology and confomational changes.
The transmembrane domain (TMD) of membrane proteins has emerged as a promising yet challenging target for drug discovery due to its hydrophobic nature and complex structure. Recent advances in structural biology and computational tools have provided unprecedented insights of TMDs, revealing new opportunities for therapeutic intervention with small molecules, particularly through interactions at the protein-lipid interface. This perspective explores the structural characteristics of TMDs and the challenges associated with targeting them. It explores the mechanisms by which small molecules can modulate TMD function, focusing on ligand diffusion, partitioning, and conformational changes within the membrane. We highlight the transformative potential of TMD-targeted therapies and emphasize the critical role of the lipid environment in regulating membrane protein function. Through a comprehensive analysis of emerging trends and future directions, this perspective highlights the significance of TMD-targeted drug design in reshaping the landscape of pharmaceutical innovation.
No takes yet. Share an insight, caveat, or question.
Wang et al. (2025) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: